The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2019 | Improving AML outcomes
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, gives an overview of what we can expect to see from future acute myeloid leukemia (AML) clinical trials in the UK and how patient outcomes can be improved with the ongoing research that is currently underway. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
